<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Cefoxitin - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Cefoxitin</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Cefoxitin</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Cefoxitin 1gm Powder for Injection</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Moderate to severe infections (intra-abdominal, gynecologic, skin/soft tissue)</strong>
            <ul>
              <li>1–2 g IV every 6–8 hours</li>
              <li>Severe infections: 2 g IV every 6 hours or 3 g IV every 8 hours (up to 12 g/day)</li>
            </ul>
          </li>
          <li><strong>Surgical prophylaxis</strong>
            <ul>
              <li>2 g IV within 30–60 minutes before incision</li>
              <li>Redose 2 g IV every 2–3 hours during prolonged procedures (shorter half-life than cefazolin)</li>
              <li>Postoperative: may continue 2 g IV every 6 hours for 24 hours (per protocol)</li>
            </ul>
          </li>
          <li><strong>Pelvic inflammatory disease (inpatient treatment)</strong>
            <ul>
              <li>2 g IV every 6 hours (usually in combination with doxycycline)</li>
            </ul>
          </li>
          <li><strong>Uncomplicated gonorrhea (when cephalosporin indicated; less common now)</strong>
            <ul>
              <li>2 g IM single dose plus probenecid 1 g PO (historical; verify current guidelines)</li>
            </ul>
          </li>
          <li><strong>Renal impairment dosing</strong>
            <ul>
              <li>Dose reduction required: follow product monograph based on creatinine clearance</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Intra-abdominal infections (peritonitis, abscesses, appendicitis, diverticulitis)</li>
          <li>Gynecologic infections (endometritis, pelvic inflammatory disease, pelvic cellulitis)</li>
          <li>Skin and soft tissue infections</li>
          <li>Bone and joint infections</li>
          <li>Surgical prophylaxis (especially colorectal, gynecologic, and other procedures requiring anaerobic coverage)</li>
          <li>Second-generation cephalosporin (cephamycin) with good anaerobic coverage (including B. fragilis)</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to cefoxitin or other cephalosporins</li>
          <li>History of immediate/severe hypersensitivity to penicillins (risk of cross-reactivity; assess severity and type of reaction)</li>
          <li>Renal impairment: dose adjustment required to prevent accumulation</li>
          <li>C. difficile-associated diarrhea risk: reassess if significant diarrhea develops during/after therapy</li>
          <li>Not effective against MRSA, Enterococcus, or Pseudomonas</li>
          <li>Caution with concurrent nephrotoxic agents</li>
          <li>May cause false-positive urine glucose tests (copper reduction methods; does not affect glucose oxidase methods)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Injection site reactions (pain, thrombophlebitis, inflammation)</li>
          <li>Hypersensitivity reactions (rash, urticaria; rarely anaphylaxis)</li>
          <li>GI upset (nausea, diarrhea)</li>
          <li>C. difficile-associated diarrhea</li>
          <li>Elevated liver enzymes (transient)</li>
          <li>Hematologic effects (eosinophilia, thrombocytopenia, leukopenia – uncommon)</li>
          <li>Nephrotoxicity (rare; dose-related)</li>
          <li>Hypoprothrombinemia (rarely; more common with high doses/prolonged therapy)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>Reconstitution:</strong> Reconstitute powder with sterile water for injection or 0.9% sodium chloride per manufacturer's instructions</li>
          <li><strong>IV administration:</strong> May give as slow IV push over 3–5 minutes or dilute further and infuse over 30–60 minutes</li>
          <li><strong>IM administration:</strong> May be given IM for selected indications (painful; use large muscle mass)</li>
          <li>Administer at evenly spaced intervals to maintain therapeutic levels</li>
          <li>Discard unused reconstituted solution per stability guidelines (typically 24 hours refrigerated; verify product-specific information)</li>
          <li>Inspect for particulate matter and discoloration before administration</li>
          <li>Do not mix with aminoglycosides in the same IV line (incompatibility)</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response within 48–72 hours (fever, infection signs, symptoms)</li>
          <li>Allergy/hypersensitivity reactions (rash, anaphylaxis): stop immediately if anaphylaxis suspected</li>
          <li>Renal function (baseline and during therapy if prolonged course or high risk)</li>
          <li>Diarrhea severity (assess for C. difficile if severe/persistent)</li>
          <li>IV site for phlebitis/infiltration</li>
          <li>CBC and coagulation parameters if prolonged therapy (monitor for hematologic effects and hypoprothrombinemia)</li>
          <li>Liver function tests if prolonged therapy</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Excellent choice for intra-abdominal and gynecologic infections due to anaerobic coverage (including B. fragilis)</li>
          <li>Surgical prophylaxis: shorter half-life than cefazolin requires more frequent redosing during prolonged procedures</li>
          <li>Confirm indication and avoid antibiotics for likely viral/self-limited illness when possible (stewardship)</li>
          <li>If diagnostics are limited, reassess early non-response and consider alternate diagnosis or need for escalation/evac</li>
          <li>Ensure proper reconstitution and storage; document preparation date/time</li>
          <li>Document start date, dose, planned duration, and allergy status clearly</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (Cefoxitin for Injection): <a href="https://pdf.hres.ca/dpd_pm/00049841.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00049841.PDF</a></li>
          <li>Sanford Guide to Antimicrobial Therapy (subscription): <a href="https://www.sanfordguide.com/" target="_blank" rel="noopener">https://www.sanfordguide.com/</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
